Article Text

PDF
Case series
Thrombectomy 24 hours after stroke: beyond DAWN
  1. Shashvat M Desai1,
  2. Diogo C Haussen2,
  3. Amin Aghaebrahim3,
  4. Alhamza R Al-Bayati2,
  5. Roberta Santos3,
  6. Raul G Nogueira2,
  7. Tudor G Jovin1,
  8. Ashutosh P Jadhav1
  1. 1University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
  2. 2Emory University/Marcus Stroke & Neuroscience Center-Grady Memorial Hospital, Atlanta, Georgia, USA
  3. 3Lyerly Neurosurgery, Baptist Neurological Institute, Jacksonville, Florida, USA
  1. Correspondence to Dr Ashutosh P Jadhav, University of Pittsburgh, Pittsburgh, PA 15218, USA; jadhavap{at}upmc.edu

Abstract

Background and purpose The results of the DAWN trial support the benefit of thrombectomy in patients with anterior circulation large vessel occlusion (LVO) acute stroke presenting within 6–24 hours from time last known well (TLKW). We sought to evaluate the characteristics and outcomes of patients who met DAWN criteria but underwent thrombectomy beyond 24 hours of TLKW.

Methods A retrospective review of endovascular thrombectomy databases at three comprehensive stroke centers was performed to identify all patients who received thrombectomy beyond 24 hours of TLKW and otherwise met the DAWN criteria. Baseline characteristics, efficacy, and safety outcomes were compared with patients in the DAWN trial intervention arm.

Results Twenty-one patients met the inclusion criteria. Rates of successful reperfusion (mTICI2b–3: 81% vs 84%, P=0.72), 90-day functional independence (modified Rankin Scale score 0–2, 43% vs 48%, P=0.68), and symptomatic intracranial hemorrhage (5% vs 6%, P=0.87) were comparable across the two groups.

Conclusion Thrombectomy appears to be safe and feasible in patients with acute ischemic stroke due to LVO meeting all DAWN trial criteria but treated beyond 24 hours of TLKW with outcomes comparable to patients in the DAWN trial intervention arm. Further studies are warranted to validate these findings.

  • intervention
  • stroke
  • thrombectomy

Statistics from Altmetric.com

Footnotes

  • Contributors Conception and design: APJ. Acquisition of data: all authors. Analysis and interpretation of data: all authors. Drafting the article: SMD. Critically revising the article: all authors. Administrative/technical/material support: all authors. Study supervision: APJ.

  • Competing interests TGJ: Consultant: Neuravi (Steering Committee - modest), Codman Neurovascular (DSMB - modest), Stryker Neurovascular (PI DAWN - unpaid), Fundacio Ictus (PI REVASCAT - unpaid). Stock: Anaconda, Silk Road, Blockade Medical (modest). RGN: Stryker-Neurovacular (Trevo-2 & DAWN Trial PI), Covidien (SWIFT & SWIFT PRIME/Steering Committee, STAR Trial/ Core Lab), Penumbra (3-D Separator Trial/Executive Committee).

  • Patient consent Not required.

  • Ethics approval Ethics approval was obtained from the Institutional Review Boards of University of Pittsburgh, Emory University, and Lyerly Neurosurgery, Baptist Neurological Institute.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.